GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » YoY EBITDA Growth

DT&CRO Co (XKRX:383930) YoY EBITDA Growth : 71.15% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is DT&CRO Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. DT&CRO Co's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was 71.15%.

DT&CRO Co's EBITDA per Share for the three months ended in Sep. 2024 was ₩-35.33.

DT&CRO Co YoY EBITDA Growth Historical Data

The historical data trend for DT&CRO Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DT&CRO Co YoY EBITDA Growth Chart

DT&CRO Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- 1,056.37 1.03 -220.17

DT&CRO Co Quarterly Data
Jun21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -149.35 -1,289.41 -248.59 -170.42 71.15

DT&CRO Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

DT&CRO Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1019.01-847.959)/ | 847.959 |
=-220.17 %

DT&CRO Co's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-35.332--122.478)/ | -122.478 |
=71.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DT&CRO Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of DT&CRO Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

DT&CRO Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DT&CRO Co Ltd (XKRX:383930) » Definitions » YoY EBITDA Growth
Comparable Companies
XKRX:222110 XKRX:185490 XKRX:263050 XKRX:296160 XKRX:038070 XKRX:261780 XKRX:314130 XKRX:365270 XKRX:067370 XKRX:284620 VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
N/A
Address
28, Baengnyeong-ro 20beon-gil, 2nd, 3rd, 4th floor, Na-dong, Cheoin-gu, Gyeonggi-do (Yubang-dong), Yongin-si, KOR, 17042
Website
http://www.dtncro.com
DT&CRO Co Ltd conducts a series of consigned research, from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional foods, cosmetics and medical devices, to analysis, bioactivity, clinical trials, and licensing consulting. provided as a service.

DT&CRO Co Headlines

No Headlines